Download PDF
Onkologische Welt 2011; 02(03): 137-141
DOI: 10.1055/s-0038-1631257
Kongressnachlese: EAU 2011
Schattauer GmbH

Von Standardtherapien und kontroversen Ansätzen: Translationale Forschung und multidisziplinärer Ansätze in der Uro-Onkologie

Peter Henning Dr.
Further Information

Publication History

Publication Date:
03 February 2018 (online)

Also available at
    Permissions and Reprints

Die gemeinsame Sitzung von EORTC GU, ESUR und ESOU diskutierte im Rahmen des EAU umfassend die modernsten Standardtherapien und kontroverse Ansätze in der Uro-Onkologie.

 

  • Literatur

  • 1 de Bobo JS. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-1154.
    CrossrefGoogle Scholar
  • 2 Wilson PG, Fuller MT. Borisy. Monastral bipolar spindles: implications for dynamic centrosome organisation. Journal of Cell Science 1997; 110: 541-464.
    Google Scholar
  • 3 Paul et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nature Reviews Drug Discovery 2010; 9: 203-214.
    CrossrefGoogle Scholar
  • 4 Bray F.. et al. Estimates of cancer incidence and mortality in Europe in 1995. EJC 2002; 38: 99-166.
    CrossrefGoogle Scholar
  • 5 Lorch A.. et al. Conventional-dose versus high-dose chemotherapy in relapsed or refractory male germ-cell tumors: A retrospective study in 1,594 patients. ASCO. 2010; J Clin Oncol 201 (28) 15s (suppl; abstr 4513).
    Google Scholar
  • 6 Reid AHM. et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28: 1489-1495.
    CrossrefGoogle Scholar
  • 7 Attard G. et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27: 3742-3748.
    CrossrefPubMedGoogle Scholar
  • 8 Scher HI. et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet 2010; 375: 1437-1446.
    CrossrefGoogle Scholar
  • 9 Heidenreich AH. et al. EAU guideline on clinically localized prostate cancer: Compliance among urologists concerning diagnosis, staging and treatment. Eur Urol Suppl 2011; 10 Abstr. #302.
    Google Scholar
  • 10 Ruprecht O. et al. MRI of the prostate: Interobserver agreement compared with histopathologic outcome after radical prostatectomy. Eur J Radiol. 2011 Feb 26. [Epub ahead of print].
    Google Scholar
  • 11 Garely et al. 2011
  • 12 Im Blickpunkt. Der 800-Millionen-Dollar-Mythos…wa skostet die Entwicklung eines Arzneimittels wirklich?. arznei-telegramm 2011; 42: 41-43.
    Google Scholar
  • 13 Light DW, Warburton R. BioSocieties 2011; 6: 34-50.
    Crossref